In the last trading session, 12.36 million shares of the Omega Therapeutics Inc (NASDAQ:OMGA) were traded, and its beta was 1.66. Most recently the company’s share price was $0.12, and it changed around $0.0 or -7.13% from the last close, which brings the market valuation of the company to $6.42M. OMGA currently trades at a discount to its 52-week high of $4.46, offering almost -3616.67% off that amount. We note from Omega Therapeutics Inc’s average daily trading volume that its 10-day average is 5.27 million shares, with the 3-month average coming to 924.56K.
Omega Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended OMGA as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Omega Therapeutics Inc is expected to report earnings per share of -0.24 for the current quarter.
Omega Therapeutics Inc (NASDAQ:OMGA) trade information
Instantly OMGA has showed a red trend with a performance of -7.13% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.5000 on recent trading dayincreased the stock’s daily price by 76.0%. The company’s shares are currently down -84.44% year-to-date, but still down -76.33% over the last five days. On the other hand, Omega Therapeutics Inc (NASDAQ:OMGA) is -86.48% down in the 30-day period. We can see from the shorts that 6.36 million shares have been sold at a short interest cover period of 16.34 day(s).
The consensus price target as assigned by Wall Street analysts is $9, which translates to bulls needing to increase their stock price by 98.67% from its current value. Analyst projections state that OMGA is forecast to be at a low of $7 and a high of $11.
Omega Therapeutics Inc (OMGA) estimates and forecasts
The year-over-year growth rate is expected to be 145.83%, up from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of 500k in revenue for the current quarter. 2 analysts expect Omega Therapeutics Inc to make 675k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 989k and 2.36M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -49.44%. Forecasts for the next quarter put sales growth at -71.40%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -48.08%.
OMGA Dividends
Omega Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Omega Therapeutics Inc (NASDAQ:OMGA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.62% of Omega Therapeutics Inc shares, and 90.43% of them are in the hands of institutional investors. The stock currently has a share float of 91.92%. Omega Therapeutics Inc stock is held by 70.0 institutions, with FLAGSHIP PIONEERING INC. being the largest institutional investor. By 2024-06-30, it held 52.9924% of the shares, which is about 29.23 million shares worth $60.5 million.
FMR LLC, with 11.3181% or 6.24 million shares worth $12.92 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Nov 30, 2024 . The former held 2.01 shares worth $0.23 million, making up 3.63% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 779.1 shares worth around $90375.0, which represents about 1.41% of the total shares outstanding.
